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Abstract
Research in rheumatoid arthritis (RA) is increasingly focused on the discovery of biomarkers
that could enable personalized treatments. The genetic biomarkers associated with the
response to TNF inhibitors (TNFi) are among the most studied. They include 12 SNPs
exhibiting promising results in the three largest genome-wide association studies (GWAS).
However, they still require further validation. With this aim, we assessed their association
with response to TNFi in a replication study, and a meta-analysis summarizing all non-
redundant data. The replication involved 755 patients with RA that were treated for the first
time with a biologic drug, which was either infliximab (n = 397), etanercept (n = 155) or adali-
mumab (n = 203). Their DNA samples were successfully genotyped with a single-base
extension multiplex method. Lamentably, none of the 12 SNPs was associated with
response to the TNFi in the replication study (p > 0.05). However, a drug-stratified explor-
atory analysis revealed a significant association of the NUBPL rs2378945 SNP with a poor
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response to etanercept (B = -0.50, 95% CI = -0.82, -0.17, p = 0.003). In addition, the meta-
analysis reinforced the previous association of three SNPs: rs2378945, rs12142623, and
rs4651370. In contrast, five of the remaining SNPs were less associated than before, and
the other four SNPs were no longer associated with the response to treatment. In summary,
our results highlight the complexity of the pharmacogenetics of TNFi in RA showing that it
could involve a drug-specific component and clarifying the status of the 12 GWAS-drawn
SNPs.
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease that until the late 1990s led to
permanent disability, low life quality and increased mortality [1]. The development of targeted
drugs, pioneered by TNF inhibitors (TNFi), transformed this poor clinical evolution. Now, it
is possible to obtain long-term clinical remission or low disease activity in an important pro-
portion of patients [1,2]. The remaining patients (about 30%) will not appropriately respond
to a specific drug although they may respond to another. Therefore, biomarkers for prediction
of the response will improve the benefits and avoid the unnecessary costs and side effects of
the targeted drugs [3,4].
The goal of predicting the response to treatment in RA patients has been pursued in many
research areas [3,4]. One of these areas has been genetics, where candidate-gene and genome-
wide studies (GWAS) have been performed [5,6]. They have been primarily concentrated on
the response to three TNFi: infliximab, adalimumab, and etanercept, as the most widely used
biologic Disease Modifying Anti-Rheumatic Drug (bDMARD). The initial studies were
focused on candidate genes, with many addressing the TNFα gene [7,8]. These studies were
small, probably expecting polymorphisms with an important influence in the drug effect [6,9].
Unfortunately, their findings were not reproducible showing the initial expectations were too
optimistic [6,8,10–12]. More recently, several large studies have been reported including many
hundreds or thousands of RA patients [12–17]. They have demonstrated promising SNPs that
are associated with the response to TNFi at various levels of evidence. Some appeared in candi-
date-gene studies, as the PTPRC rs10919563 SNP, which approached the GWAS-level of sig-
nificance combining three large studies [15–17]. Others have been highlighted in GWAS [11–
14,18,19], like the four SNPs we attempted to validate in a previous work [20], and the 12 SNPs
that we have selected now.
We have drawn these 12 SNPs from the three largest published GWAS [12–14]. Two of
them included the same� 2700 patients that were analyzed according to different protocols
[12,14], while the third GWAS counted with 1278 patients [13]. The 12 SNPs fulfilled the
requirements of replicability established on the respective GWAS, although none of them
reached the GWAS-level of significance (p< 5 x10-8). Nevertheless, the CD84 rs6427528 was
associated with p = 8 x10-8, but only with the response to etanercept, not with the response to
infliximab or adalimumab [14]. This result signaled the possibility of drug-specific biomarkers
within the response to the TNFi. Indeed, other studies have shown drug-specific genetic
[19,21–23] and protein biomarkers [24]. This specificity could be consequence of the known
differences in structure, pharmacokinetics and interactions between the three TNFi [25,26].
Therefore, we have addressed the replication of the 12 SNPs considering the three TNFi
together and separately. In addition, we have completed the SNPs assessment by meta-analysis
to combine our results with the data from previous studies.
12 GWAS-drawn SNPs in RA response to TNFi
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Material and methods
Patients
A total of 788 patients with RA according to the American College of Rheumatology classifica-
tion criteria [27] were included. They were either of self-reported Spanish European ancestry
(n = 731) recruited in 15 Spanish Rheumatology Units, or of Greek European ancestry
recruited in two Greek hospitals (n = 57). All provided blood samples for DNA extraction and
their informed written consent. The study was conducted according to the principles of the
Declaration of Helsinki (2013) and was approved by the Comite´ E´tico de Investigacio´n Clı´nica
del Hospital Clı´nic de Barcelona, the Comite´ E´tico de Investigacio´n Clı´nica de Centro de Gra-
nada, University of Thessaly and Medical School Ethics Committee, the Comite´ E´tico de
Investigacio´n Clı´nica del Hospital 12 de Octubre, the Comite´ de E´tica de la Investigacio´n con
Medicamentos del Hospital La Paz, the Comite´ E´tico de Investigacio´n del Hospital Virgen de
la Arrixaca, the Comite´ de E´tica de la Investigacio´n del Hospital Regional Universitario Carlos
Haya, the Comite´ E´tico de Investigacio´n Clı´nica del Hospital Universitario Doctor Peset, the
Comitè d’E`tica d’Investigacio´ Clı´nica de l’Hospital Universitari de Bellvitge, the Comite´ de
E´tica de la Investigacio´n de los Hospitales Universitarios Virgen Macarena-Virgen del Rocı´o,
the Comite´ de E´tica de la Investigacio´n con Medicamentos del Hospital Universitario Gregorio
Maraño´n, the Comite´ de E´tica de la Investigacio´n Ma´laga Noroeste, the Comite´ de Bioe´tica del
Consejo Superior de Investigaciones Cientı´fica and by the Comite Etico de Investigacion Clin-
ica de Galicia (Santiago de Compostela, Spain). All the patients were treated with a TNFi as the
first bDMARD between 2000 and 2011. The indication of treatment, the choice of drug, and
the control of clinical evolution were performed with independence of this study during the
standard care of the patients. Evaluations included Disease Activity Score 28 (DAS28) at the
start of treatment and at 3, 6, and 12 months. DAS28 is a composite index of RA activity
including the number of tender joints and swollen joints (28 joints maximum), erythrocyte
sedimentation rate, and global patient health status assessment [28]. Patients with baseline
DAS28 < 3.2 (i.e. showing low activity, n = 13), and samples failing most genotypes (n = 20)
were excluded from further analysis. The remaining 755 patients were distributed as follows:
397 treated with infliximab, 155 treated with etanercept, and 203 treated with adalimumab.
Their clinical characteristics are detailed in Table 1. We have sufficient information to analyze
response to treatment of 452 patients at 3 months, 689 patients at 6 months and 531 at 12
months. The corresponding raw data are provided in Supporting information S1 Table.
Genotyping assays
Twelve SNPs (Table 2) were selected because of their reported association with response to
TNFi in published GWAs [12–14]. These SNPs were genotyped with a multiplex single-base
extension technology (SNaPshot Multiplex Kit from Applied Biosystems, Foster City, CA)
starting with DNA amplification in a multiplex PCR reaction (KAPA2G fast HotStart, Kapa
Biosystems, Woburn MA). Ten per cent of the samples were re-genotyped for quality control.
Primers and probes used for these analyses are available in Supporting Information S2 Table.
Statistical analyses
We have used reproducibility of genotypes, genotype call rate, the Hardy-Weinberg equilib-
rium (HWE) and coincidence with SNP frequencies in the HapMap Toscani in Italy (TSI) col-
lection [29] as quality control measures. The response to TNFi was assessed primarily as
change in DAS28 (ΔDAS28 = DAS28 baseline−DAS28follow-up) at 6 months of follow-up. Addi-
tionally, we have also considered ΔDAS28 at the 3 and 12 month points and the responder
12 GWAS-drawn SNPs in RA response to TNFi
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(good + moderate) versus non-responder classification according to the European League
Against Rheumatism (EULAR) criteria [30]. The EULAR criteria divide patients into three
classes based on change in DAS28 from baseline (ΔDAS28) and DAS28 at the time of evalua-
tion: good responders are those with ΔDAS28� 1.2 and DAS28� 3.2; non-responders are all
patients with ΔDAS28� 0.6 and those with ΔDAS28 > 0.6 but� 1.2 and with DAS28 > 5.1;
all the remaining patients are moderate responders. Generalized linear models for ΔDAS28
and logistic regression models for EULAR response criteria were fitted. Genotypes were con-
sidered according to an additive genetic model of minor allele counts (0, 1 or 2). Therefore
positive regression coefficients indicate a better response associated with minor allele additive
effects. Covariates included in the models were baseline DAS28, gender, the specific TNFi, and
the Spanish or Greek origin. Statistica 7.0 (Statsoft, Tulsa OK) software was used to perform
these analyses. Meta-analysis of the current study with all the available non-redundant results
from previous studies was done. Specifically, information from 2466 patients included in
Table 1. Characteristics of the 755 patients with RA included in the study.
Characteristic Value
Female N (%) 624 (82.7)
Age at diagnosis, mean ± SD years 43.2 ± 14.1
Diagnosis to TNFi treatment, mean ± SD years 7.9 ± 7.5
Rheumatoid factor positive, N (%) 560 (74.4)
Anti-CCP positive, N (%)� 423 (70.6)
Erosive arthritis. N (%)� 422 (70.7)
Ever smokers, N (%)� 100 (20.0)
DAS28 at baseline, mean ± SD 5.8 ± 1.1
HAQ at baseline, mean ± SD� 1.5 ± 0.7
Concomitant DMARDs, N (%) 547 (95.0)




EULAR response, N (%)
3 months (N = 452)
good 137 (30.3)
moderate 221 (48.9)
non responder 94 (20.8)
6 months (N = 689)
good 262 (38.0)
moderate 291 (42.2)
non responder 136 (19.7)
12 months (N = 531)
good 242 (45.6)
moderate 193 (36.4)
non responder 96 (18.1)
� Data was available from <85% of the patients: 599 for anti-CCP antibodies, 597 for erosive arthritis, 501 for
smoking, 528 for baseline HAQ and 576 for concomitant DMARDs.
Abbreviations: DMARD = disease-modifying anti-rheumatic drug; SD = standard deviation; DAS28 = Disease
Activity Score 28 joints; HAQ = Health Assessment Questionnaire; EULAR = The European League Against
Rheumatism.
https://doi.org/10.1371/journal.pone.0213073.t001
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previous studies and from 689 patients from the current study at 6 months was available corre-
sponding to the three SNPs selected from Plant et al. [13]. The previous information was
reported in [13] as stages 1 (WTCCC, n = 566), 2 (n = 379) and 3 (n = 341) from the UK; in
[11] as the DANBIO register (n = 196); and in [12] as the stage 1 (combining two Dutch collec-
tions, n = 984). In turn, there were data from 3155 non-redundant patients corresponding to
the eight Umicevic Mirkov et al. [12] SNPs. This information was available in a previous study
[12] as four sample collections: stage 1 (jointly including Dream and ApotheekZorg, n = 882),
stage 2 (REF collection, n = 954), WTCCC (n = 595) and ReAct (n = 272), and in the current
study as 452 patients assessed at 3 months of follow-up. Finally, there was information for
rs6427528 from 1178 patients treated with etanercept and assessed at any time from 3 to 12
months. They were reported in the current (n = 155) and previous studies (n = 1023) [14]. Pre-
vious collections were: REF (n = 365), BRAGGSS (n = 259), DREAM (n = 109), Portuguese
(139), Kyoto (n = 88) and IORRA (n = 63). The reader is referred to the original manuscripts
for the detailed definition of each sample collection. In addition, it should be noted that the
number of patients included in the different studies, at different times or for different SNPs
was variable. For example, the patients identified as WTCCC were not exactly the same in [13]
and in [12], two studies that were evaluated at different times. Also, the number of samples
used in [12] to replicate the SNPs from Plant et al. [13] was slightly different than the used to
discover new associations. All these patient sets were combined with the fixed effects model of
meta-analysis, weighting each cohort by the inverse variance method, except for SNPs showing
significant heterogeneity (I2 > 50%). In this latter case, the random effects model according to
DerSimonian and Laird was applied. These analyses were conducted with the R metafor pack-
age [31]. Post-hoc power analysis was conducted with G�Power 3 considering the response to
treatment at any time [32].
Results
The 755 patients with RA showed characteristics of a severe disease before starting treatment
with TNFi (Table 1). This was indicated by frequent erosive arthritis (70.7%), high disease
activity (mean DAS28 = 5.8) and moderate to severe disability (mean HAQ = 1.5). The patients
Table 2. SNPs associated with response to TNFi in RA GWAS selected for this study.
Discovery SNP Location p
Plant et al. a rs7962316 BC118985/BTP1 0.02
rs1350948 Chr11: 23518405 0.008
rs4694890 TEC 0.006
Umicevic Mirkov et al. a rs2378945 NUBPL 0.0007
rs12142623 Chr1: 185557029 0.0002
rs1568885 Chr7: 13604056 0.00017




rs7767069 Chr6: 68827284 0.00008
Cui et al. a rs6427528 CD84 0.00000008 b
a The three GWAS used ΔDAS28 as outcome, including 1278, 2703 and 2706 partly overlapping sets of RA patients, respectively. Assessment was done at 6 months, 14
weeks and at any time between 3 and 12 months, respectively.
b Only in the 733 RA patients treated with etanercept.
https://doi.org/10.1371/journal.pone.0213073.t002
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presented this level of severity at the baseline in spite of previous treatment with a mean of
2.64 different conventional DMARDs. None of these previous drugs included a bDMARD as
this was one of the exclusion criteria in our project. The patients received any of the three
most common TNFi during the period of assessment, infliximab (52.6%), etanercept (20.5%)
or adalimumab (26.9%). The TNFi were given in parallel with a conventional DMARD in
95.0% of the patients. However, treatment was inefficient in some patients, with a percentage
of non-responders according to the EULAR criteria that remained fairly constant at the three
evaluation times: between 18.1 and 20.8% (see Supporting information S3 Table for the drug-
stratified data).
In our attempt to validate biomarkers of response to TNFi, we analyzed the 12 SNPs from
GWAS in Table 2. Their genotypes passed quality control criteria, including call rate (> 99%),
reproducibility (100%), fit to HWE (P> 0.05), and consistency with HapMap frequencies (all
pair-wise comparisons P> 0.05). Unfortunately, linear regression did not show any significant
association between the 12 SNPs and the predefined main outcome of response, ΔDAS28 at 6
months (Table 3), or with the secondary outcomes, ΔDAS28 at 3 or at 12 months (Table 3).
Similarly, logistic regression did not show association of the SNPs with the non-responder vs.
responder classification of the patients (S4 Table). In addition, the CD84 SNP rs6427528,
which was specifically associated with the response to etanercept in a previous GWAS [14],
was not associated in this subset of our patients (B = 0.16, 95% CI -0.43, 0.76, p = 0.6 for
ΔDAS28 at 3 months; and OR = 1.16, 95% CI (0.68–1.97), p = 0.6 for the responder vs. non-
responder comparison; and similar results at 6 or 12 months).
Considering the convenience of summarizing the results, we performed post-hoc power
analysis of our results, and combined meta-analysis with the previous data. The power analysis
showed our study had only enough post-hoc power (1-β> 80%) to reproduce the rs4694890
and rs7767069 reported associations, with rs1350948 very near this level (77%). For the
remaining SNPs, power was insufficient and assessment of their status relies more heavily in
the combined meta-analysis than in the replication. The meta-analysis (Table 4) included a
total of 3155 patients with information for the 3 SNPs identified by Plant et al. [13], and the
same number, but not exactly the same patients, for the 8 SNPs drawn from Umicevic Mirkov
et al. [12]. In turn, there were a total of 1178 patients treated with etanercept with information
for the rs6427528 SNP identified by Cui et al. [14]. Three of the 12 associations were slightly
reinforced by the meta-analysis including our results (Fig 1). The association of rs2378945
changed from p = 6.9 x10-4 to 1.8 x10-4; the corresponding to rs12142623 passed from p = 2.0
x10-4 to 4.2 x10-5; and the change for rs4651370 was from p = 1.1 x10-4 to 5.6 x 10−5. In con-
trast, four other SNPs were no longer associated with response to treatment and the remaining
five SNPs showed decreased associations (Table 4).
To complete our study, we included an exploratory analysis stratified by the different TNFi.
In this exploration, we uncovered association of the NUBPL rs2378945 SNP at 3 months with
ΔDAS28 only in the etanercept-treated patients (Fig 2, B = -0.50, 95% CI (-0.82, -0.17),
p = 0.003). This result represented less decrease of DAS28 in the patients bearing the minor
allele of rs2378945. The association with reduced response was also reflected in the analysis of
the EULAR response. In effect, the minor allele of rs2378945 was associated with less good
responders compared with moderate responders and non-responders considered together
(OR = 0.54, 95% CI = 0.31–0.96, p = 0.035), without significant distinction between moderate
responders and non-responders (p = 0.7). The circumscribed association to the 3-month eval-
uation could be due to the progressive improvement observed in the patients treated with eta-
nercept (non-responders changed from 20.9% at 3 months to 8.3% and 7.2% at 6 and 12
months, respectively). An improvement that was not observed in patients treated with the
other TNFi (S3 Table).
12 GWAS-drawn SNPs in RA response to TNFi
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Discussion
None of the 12 GWAS-drawn SNPs showed association with the response to TNFi in our RA
patients. This lack of replication is important because the SNPs were from high-quality studies
and this is the first attempt of independent replication for 9 of them. Nevertheless, the combi-
nation of our results with the previous studies discriminated between 3 SNPs that showed
strengthened association and the remaining 9 SNPs whose status was weakened without ques-
tion. In any case, the low level of reproducibility reinforces the need for circumspect consider-
ation and calls for more powerful studies. In this regard, the association of NUBPL rs2378945
with the specific response to etanercept could reflect the phenotype complexity.
Two of the three associations that were reinforced by our results could be considered as
only one because rs12142623 and rs4651370 are near and in high linkage disequilibrium
Table 3. Results of the linear regression of SNP genotypes on the ΔDAS28 at the indicated times under TNFi treatment.
SNP Mi/Ma1 3 mo. 6 mo. 12 mo.
B SE p B SE p B SE p
rs12142623 T/G 0.23 0.13 0.07 0.11 0.1 0.3 - 0.17 0.13 0.2
rs1568885 T/A 0.06 0.12 0.6 0.03 0.1 0.7 0.10 0.12 0.4
rs2378945 A/G - 0.14 0.09 0.10 0.05 0.07 0.5 - 0.10 0.09 0.2
rs4651370 A/T 0.14 0.12 0.3 0.05 0.1 0.6 - 0.19 0.13 0.14
rs1447722 C/G - 0.05 0.09 0.5 - 0.04 0.07 0.5 0.08 0.09 0.4
rs1813443 G/C 0.04 0.10 0.7 - 0.05 0.07 0.5 - 0.05 0.09 0.6
rs4411591 A/G 0.01 0.12 0.9 0.02 0.09 0.8 0.07 0.11 0.6
rs7767069 T/A - 0.06 0.10 0.6 <0.01 0.08 1.0 - 0.08 0.09 0.4
rs7962316 G/A 0.09 0.09 0.4 0.06 0.07 0.4 - 0.01 0.09 0.9
rs1350948 A/G <0.01 0.11 1.0 0.042 0.09 0.6 0.01 0.11 0.9
rs4694890 A/C - 0.05 0.08 0.6 0.07 0.07 0.3 - 0.01 0.08 0.9
rs6427528 A/G <0.01 0.13 1.0 - 0.04 0.11 0.7 0.01 0.13 0.9
1 Minor/major alleles. B = regression coefficient and SE, its standard error.
https://doi.org/10.1371/journal.pone.0213073.t003
Table 4. Summary statistics of the meta-analysis combining the current and previous studies.
SNP Coefficient CI p I2
rs7962316 0.07a -0.07, 0.20 0.3 69
rs1350948 0.12a -0.02, 0.25 0.09 58
rs4694890 -0.03a -0.16, 0.10 0.6 74
rs2378945 -0.12 -0.18, -0.06 0.0002 45
rs12142623 0.19 0.10, 0.28 0.00004 38
rs1568885 0.17 0.08, 0.26 0.0002 0
rs1447722 0.07a -0.05, 0.19 0.2 64
rs1813443 -0.12 -0.19, -0.05 0.0007 21
rs4651370 0.18 0.10, 0.27 0.00006 32
rs4411591 0.17 0.08, 0.26 0.0002 0
rs7767069 -0.13 -0.20, -0.07 0.0001 38
rs6427528b 0.33a 0.03, 0.64 0.03 66
a Random effects meta-analysis was used because of significant heterogeneity
b Only patients treated with etanercept, n = 1178
https://doi.org/10.1371/journal.pone.0213073.t004
12 GWAS-drawn SNPs in RA response to TNFi
PLOS ONE | https://doi.org/10.1371/journal.pone.0213073 February 28, 2019 7 / 14
Fig 1. Meta-analysis of the three SNPs showing reinforced association with the current study. The coefficients of
the regression with their 95% confidence intervals from each cohort and their fixed effects summary are presented. The
forest plots correspond to A) rs2378945, B) rs12142623 and C) rs4651370. The Stage 1, Stage 2, WTCCC and ReAct
data for these SNPs were exclusively reported in Umicevic Mirkov et al. [12].
https://doi.org/10.1371/journal.pone.0213073.g001
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between them (r2 = 0.90 in subjects of European descent according to the Phase 3 of the 1000
Genomes project; https://ldlink.nci.nih.gov/). They could modify the expression of the neigh-
boring PLA2G4A gene, which codes for the arachidonyl specific group IVA cytosolic phospho-
lipase 2 enzyme. This enzyme regulates TNF-induced joint damaging mediators [33]. The
other reinforced association corresponds to rs2378945, which is the same SNP we found asso-
ciated with reduced response to etanercept in the drug-stratified analysis. This SNP is associ-
ated with the expression of the nearby NUBPL gene (GTEx, http://www.gtexportal.org.),
which is a member of the ATP-binding protein family required for the assembly of the mito-
chondrial complex I. However, it has not any known relationship with inflammation or
autoimmunity.
Three of the four SNPs that were no longer associated after meta-analysis (rs7962316,
rs1350948, rs4694890) had a weak standing as biomarkers of response to TNFi even before our
study. They were associated in the two first phases, but not in the third, of the original GWAS
highlighting them [13]. Afterward, their status was further undermined by the lack of replica-
tion in two subsequent GWAS (although the time of assessment was different) [11,12]. There-
fore, our results regarding these 3 SNPs could be taken as a confirmation of their lack of
association with response to TNFi. Also, the 8 SNPs drawn from the Umicevic Mirkov et al.
[12] report had been associated with response to TNFi in the first two phases of the original
GWAS, but not in the additional replication collections from the same study [12]. The particu-
larity with these 8 SNPs is that no other work had addressed them until now. Therefore, our
study is the first independent validation and it differentiated between the three SNPs that were
reinforced and the five SNPs that were more clearly questioned. Lastly, rs6427528 showed the
Fig 2. Representation of the linear regression coefficients and their 95% CI corresponding to rs2378945 genotypes
in the multiple regression of ΔDAS28 at 3 months. The coefficients for the whole set of patients with RA (ALL) and
in the subsets treated with each of the three TNFi (IFN = infliximab, ETN = etanercept, ADM = adalimumab) are
shown.
https://doi.org/10.1371/journal.pone.0213073.g002
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strongest standing as biomarker before our study. It was associated with response to etanercept
with a p-value that approached the GWAS cut-off [14]. However, not all the evidence in the
original study was favorable to the association, and the meta-analysis of all results has shown a
very weakened association.
The lack of reproducibility we have observed adds to the circumspection advocated in other
analyses and reviews [6,23]. Currently, even the most promising biomarkers are not without
doubts. For example, the first SNP that reached the GWAS level of significance, rs3794271
[34], was not replicated in a subsequent and larger study [35]. Other example is the mentioned
rs6427528 in CD84 [14] that has been very undermined in our meta-analysis. However, there
are reasons to expect that some SNPs will be confirmed in future studies. They could be
among the SNPs that have demonstrated significant association in a meta-analysis [6], or the
associations below the 5 x10-8 threshold from two recent GWAS [18,19].
The lack of reproducibility cannot be attributed to a weak genetic component in the
response to TNFi phenotype. On the contrary, the heritability of ΔDAS28 has been estimated
at 0.59–0.71, which similar to other complex traits [36]. Nonetheless, the genetic structure of
this component seems very complex [23,37], resembling other common diseases and biologi-
cal traits as exemplified by the more than one hundred RA susceptibility loci [38]. This poly-
genic causality means that most loci have a small effect, requiring larger studies for their
identification than the available for response to TNFi.
Other aspects that could contribute to the lack of reproducibility include variability of the
response along the time and in function of the drug. The effect of time is well-known in clinical
practice, where primary and secondary failure to TNFi are distinguished [39]. In this regard,
there are some SNPs showing association with the response only at a given time of assessment
[6], as the observed in the current study with NUBL. The effect of a specific drug, in turn,
could be justified by the known differences between the TNFi [25,26]. Its potential impact on
the identification of biomarkers has been revealed by the higher heritability of the response to
the monoclonal antibodies (infliximab and adalimumab) than to etanercept (a soluble recep-
tor) [23] and several genetic studies leading to the identification of drug-specific associations
[14,19,21,22]. The specific association of the NUBPL SNP with the response to etanercept we
have found contributes to the accumulating evidence in this direction.
Another factor likely contributing to the lack of reproducibility is the heterogeneity of the
outcomes [36,40]. This issue has been poorly studied, but there are differences in heritability
between the components of the DAS28 [36]. The highest estimates of heritability were
obtained for the change in the swollen joint count (ΔSJC) and in the tender joint count
(ΔTJC). They were followed by ΔDAS28, while heritability of change in the erythrocyte sedi-
mentation rate (ΔESR) and in the general health scale (ΔVAS) were negligible [36]. Therefore,
future studies could take advantage of this information focusing on the high heritability com-
ponents. There are also reasons to prefer ΔDAS28 over the EULAR response. As a general
rule, the dichotomized variables have many disadvantages in comparison with the continuous
ones [41,42]. In consequence, ΔDAS28 should be more informative and less prone to false pos-
itive results than the EULAR response, but no study has compared their performance for the
search of biomarkers. Finally, a large within-patient variation at successive visits has been
described [40]. This variability decreased the apparent heritability of the response and reduced
the power to identify genetic biomarkers. Consequently, the use of the mean of the outcomes
assessed at short time intervals has been recommended [40].
Our study serves as an invitation to revise the search for genetic biomarkers of response to
TNFi given the difficulties encountered for their validations. It also serves to highlight the
complexity of the response phenotype, which likely involves many loci with small effects, and
heterogeneity in function of the specific drug and time of assessment. Therefore, identification
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of reproducible biomarkers will require larger collections of samples and more aggressive
patient stratification. In addition, this identification would benefit from the incorporation of
alternative and frequent measures of response.
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